Jetani et al. engineered CD8+ and CD4+ T cells expressing an FLT3-specific chimeric antigen receptor (CAR) and demonstrated strong reactivity against AML cells that express either wild-type FLT3 or FLT3 with internal tandem duplication (FLT3-ITD). Here, CD4 is linked to acute myeloid leukemia.